UroGen Pharma Ltd (URGN) — Cash Flow Reinvestment Rate

Latest as of September 2017: 13.87x

UroGen Pharma Ltd (URGN) has a Cash Flow Reinvestment Rate of 13.87x as of September 2017, reinvesting $36.02 Million (capex $20.00K plus investments $-36.00 Million) from operating cash flow of $2.60 Million. See free cash flow generation of UroGen Pharma Ltd to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

13.87x

(Capex + Investments) / Operating CF

Total Reinvested

$36.02 Million

Capex + Investments

Operating Cash Flow

$2.60 Million

USD

Capital Expenditures

$20.00K

USD

UroGen Pharma Ltd Cash Flow Reinvestment Rate (2016–2016)

Historical reinvestment intensity for UroGen Pharma Ltd across 1 annual periods. For the full cash flow conversion analysis, see URGN cash flow metrics.

Annual Cash Flow Reinvestment Rate for UroGen Pharma Ltd (2016–2016)

Year-by-year capital reinvestment analysis for UroGen Pharma Ltd. See UroGen Pharma Ltd (URGN) financial flexibility to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2016	0.36x	$1.49 Million	$4.19 Million	$695.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow